In brief, these RCTs focused on examining the treatment effectiveness of TYK2 inhibitors on plaque psoriasis and a few studied ulcerative colitis, alopecia areata, systemic lupus erythematosus, atopic dermatitis, and active non-segmental vitiligo. The gene discussed is TYK2; the disease is systemic lupus erythematosus.